Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs

Cardiovascular Research

Volumn 39, Issue 3, 1998, Pages 580-588

  Choussat, Rémi ^a,b   Hittinger, Luc ^a,b   Barbe, Fabrice ^a,b   Maistre, Geneviève ^a,b   Carayon, Alain ^a,b   Crozatier, Bertrand ^a,b   Su, Jinbo ^a,b  

^a FACULTÉ DE MÉDECINE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Conscious dogs; Endothelin; Endothelin inhibitors; Heart failure; Ventricular function

Indexed keywords

BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DOG; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARDIAC OUTPUT; CARDIAC PACING, ARTIFICIAL; DOGS; ENDOTHELIN-1; ENDOTHELINS; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; MALE; PROTEIN PRECURSORS; RECEPTORS, ENDOTHELIN; STROKE VOLUME; SULFONAMIDES; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 0032169462     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00068-6     Document Type: Article

References (35)

1. Yanagisawa M., Kurihara H., Kimura S.et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
2. Arai M., Yoguchi A., Iso T.et al. Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am J Physiol. 268:1995;H2084-H2091.
3. Thomas P.B., Liu E.C.K., Webb M.L., Mukherjee R., Hebbar L., Spinale F.G. Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure. Am J Physiol. 271(Heart Circ Physiol):1996;H2629-H2637.
4. Yanagisawa M. The endothelin system: a new target for therapeutic intervention. Circulation. 89:1994;1320-1322.
5. Lüscher T.F. Do we need endothelin antagonists? Cardiovasc Res. 27:1993;2089-2093.
6. Teerlink J.R., Breu V., Sprecher U., Clozel M., Clozel J.-P. Potent vasoconstriction mediated by endothelin ETb receptors in canine coronary arteries. Circ Res. 74:1994;105-114.
7. Seo B., Oemar B.S., Siebenmann R., Segesser L., üscher L.T. Both ETa and ETb receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 89:1994;1203-1208.
8. Haynes W.G., Strachan F.E., Webb D.J. Endothelin, ETa and ETb receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 92:1995;357-363.
9. Margulies K.B., Hildebrand F.L. Jr., Lerman A., Perrella M.A., Burnett J.C. Jr. Increased endothelin in experimental heart failure. Circulation. 82:1990;2226-2230.
10. Wei C.-M., Lerman A., Rodeheffer R.J.et al. Endothelin in human congestive heart failure. Circulation. 89:1994;1580-1586.
11. Kiowski W., Sütsch G., Hunziker P. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
12. Teerlink J.R., Carteaux J.-P., Sprecher U., Löffler B.-M., Clozel M., Clozel J.-P. Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol. 268(Heart Circ Physiol):1995;H432-H440.
13. Riegger A.J.G., Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure. Clin Sci. 62:1982;465-469.
14. Armstrong P.W., Stopps T.P., Ford S.E., Bold A. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation. 74:1986;1075-1084.
15. Wilson J.R., Douglas P., Hickey W.F.et al. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation. 75:1987;857-867.
16. Shannon R.P., Komamura K., Stambler B.S., Bigaud M., Manders W., Vatner S.F. Alterations in myocardial contractility in conscious dogs with dilated cardiomyopathy. Am J. Physiol. 260(Heart Circ Physiol 29):1991;H1903-H1911.
17. Wang W., Chen J.S., Zuker I.H. Carotid sinus baroreceptor reflex in dogs with experimental heart failure. Circ Res. 68:1991;1294-1430.
18. Komamura K., Shannon R.P., Pasipoularides A.et al. Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure. J Clin Invest. 89:1992;1825-1838.
19. Su J., Renaud N., Carayon A., Crozatier B., Hittinger L. Effects of the calcium channel blockers diltiazem and Ro 40-5967, on systemic hemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure. Br J Pharmacol. 113:1994;395-402.
20. Barbe F., Su J., Guyene T.T., Crozatier B., Ménard J., Hittinger L. Bradykinin pathway is involved in the acute hemodynamic effects of enalaprilat in conscious dogs with heart failure. Am J Physiol. 270(Heart Circ Physiol):1996;H1985-H1992.
21. Kiuchi K., Shannon R.P., Komamura K.et al. Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest. 91:1993;907-914.
22. Teerlink J.R., Löffler B.-M., Hess P., Maire J.-P., Clozel M., Clozel J.-P. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation. 90:1994;2510-2518.
23. Shimoyama H., Sabbah H.N., Borzak S.et al. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation. 94:1996;779-784.
24. Chen L., McNeill R., Wilson T.W., Gopalakrishnan V. Heterogeneity in vascular smooth muscle responsiveness to angiotensin II. Role of endothelin. Hypertension. 26:1995;83-88.
25. Ishikawa T., Yanagisawa M., Kimura S., Goto K., Masaki T. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol. 255(Heart Circ Physiol):1988;H970-H973.
26. Kasai H., Takanashi M., Takasaki C., Endoh M. Pharmacological properties of endothelin receptor subtypes mediating positive inotropic effects in rabbit heart. Am J Physiol. 266:1994;H2220-H2228.
27. Sakai S., Miyauchi T., Sakurai T.et al. Endogenous endothelin-1 participates in maintenance of cardiac function in rats with congestive heart failure. Circulation. 93:1996;1214-1223.
28. Reid J.J., Wong-Dusting H.K., Rand M.J. The effect of endothelin on noradrenergic transmission in rat and guinea-pig atria. Eur J Pharmacol. 168:1989;93-96.
29. Ishikawa T., Yanagisawa M., Kimura S., Goto K., Masaki T. Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictive peptide. Pfluger Arch. 413:1988;108-110.
30. Mulder P., Richard V., Derumeaux G.et al. Role of endogenous endothelin in chronic heart failure. Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics and cardiac remodeling. Circulation. 96:1997;1976-1982.
31. Spinale F.G., Walker D.J., Mukherjee R., Iannini J.P., Keever A.T., Gallagher K.P. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Circulation. 95:1997;1918-1929.
32. Clozel M., Breu V., Gray G.A.et al. Pharmacological characterization of bosentan a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 270:1994;228-235.
33. Cody R.J., Haas G.J., Binkley P.F., Capers Q., Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
34. Tsutamoto T., Hisanago T., Fukai D.et al. Pronostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol. 76:1995;803-808.
35. McConnell P.I., Wang W., Zucker I.H. Effects of an orally effective endothelin-A receptor antagonist in dogs with pacing-induced heart failure. Neb Med J. Nov:1996;349-355.